Top 10 Companies in the Global Medical Grade Microcrystalline Cellulose Market (2026): Market Leaders Powering Global Pharmaceutical Excipients

MARKET INSIGHTS

The Global Medical Grade Microcrystalline Cellulose (MCC) market size was valued at USD 143.80 million in 2024. The market is projected to grow from USD 153.50 million in 2025 to USD 231.65 million by 2032, exhibiting a CAGR of 7.00% during the forecast period.

Medical Grade Microcrystalline Cellulose is a purified, partially depolymerized cellulose derived from wood pulp or refined cotton. It is widely used as a binder, disintegrant, and filler in pharmaceutical formulations, particularly in tablet and capsule production, due to its excellent compressibility, stability, and inert properties. The increasing demand for pharmaceutical excipients, coupled with the growth of the generics market, is a key driver for this sector.

The market is expanding due to rising pharmaceutical production, advancements in drug delivery systems, and stringent regulatory requirements for high-quality excipients. Additionally, the growing prevalence of chronic diseases necessitates increased drug formulations, further propelling demand. Leading manufacturers like DuPont, JRS Pharma, and Roquette are investing in capacity expansion and product innovation to meet industry needs. For instance, in 2023, DuPont announced an expansion of its MCC production capacity in the U.S. to cater to the rising pharmaceutical demand, strengthening its market position.

Global Medical Grade Microcrystalline Cellulose Market – View in Detailed Research Report

Top 10 Companies in the Global Medical Grade Microcrystalline Cellulose Market (2026)

1. DuPont (USA)
   Key Offering: High‑purity MCC grades for tablet, capsule, and controlled‑release formulations.
   DuPont has leveraged its extensive R&D and global supply chain to deliver consistent, USP‑compliant MCC. In 2023 it expanded its U.S. production line, adding 200,000 metric tonnes of capacity to support the growing generic market.
   Sustainability & Growth Initiatives: Invests in renewable raw material sourcing and low‑energy hydrolysis processes.
   • Expansion of U.S. production capacity (2023)
   • Launch of high‑purity, low‑microbial MCC for biologics
   • Partnerships with leading pharma companies for next‑generation dosage forms
2. JRS Pharma (Germany)
   Key Offering: Specialty MCC grades for wet granulation and high‑performance tablets.
   JRS Pharma is a European leader in excipient technology, offering advanced MCC formulations that enhance flowability and compressibility.
   Sustainability & Growth Initiatives: Focus on circular economy practices and carbon‑neutral manufacturing.
   • Development of MCC‑silicate co‑processed excipients (2024)
   • Expansion into Asian markets via joint ventures
   • Implementation of ISO 14001 environmental management system
3. Roquette (France)
   Key Offering: Broad portfolio of MCC grades, including standard USP and high‑purity variants.
   Roquette supplies MCC to a wide range of pharmaceutical and nutraceutical manufacturers, maintaining a strong presence in Europe and North America.
   Sustainability & Growth Initiatives: Commitment to sustainable forestry and reduced water usage.
   • Launch of high‑purity MCC for injectable formulations (2025)
   • Investment in renewable energy for production sites
   • Strategic partnership with a leading biotech firm for ODT development
4. Mingtai (China)
   Key Offering: Cost‑effective MCC grades for large‑volume generic production.
   Mingtai has rapidly expanded its domestic manufacturing footprint, serving the booming Chinese generic market.
   Sustainability & Growth Initiatives: Adoption of advanced purification technologies to meet global pharmacopeia standards.
   • Opening of a new plant in Jiangsu (2024)
   • Certification of MCC grades under USP/EP/JP (2025)
   • Collaboration with local universities for R&D in controlled‑release MCC
5. Asahi Kasei (Japan)
   Key Offering: Premium MCC grades for sensitive formulations and biologics.
   Asahi Kasei is a key player in the Asia‑Pacific region, delivering high‑quality MCC with low microbial contamination.
   Sustainability & Growth Initiatives: Focus on water‑efficient processing and waste minimization.
   • Launch of low‑microbial MCC for parenteral use (2025)
   • Expansion of production capacity in Osaka (2026)
   • Collaboration with Japanese pharma for ODTs
6. Accent Microcell (India)
   Key Offering: Value‑competitive MCC grades for the Indian and regional markets.
   Accent Microcell provides cost‑effective excipients while maintaining stringent quality controls suitable for Indian GMP standards.
   Sustainability & Growth Initiatives: Implementation of energy‑saving technologies and local sourcing of raw materials.
   • Launch of high‑purity MCC for nutraceuticals (2024)
   • Partnership with a leading Indian CMO for ODTs
   • Investment in renewable energy for plant operations
7. Sigachi (India)
   Key Offering: Medium‑purity MCC for tablet and capsule manufacturing.
   Sigachi focuses on delivering reliable MCC to domestic pharma and contract manufacturers.
   Sustainability & Growth Initiatives: Adoption of ISO 9001 quality management and waste reduction programs.
   • Expansion of plant in Tamil Nadu (2025)
   • Certification of MCC grades under USP/EP (2026)
   • Collaboration with local pharma for controlled‑release formulations
8. Wei Ming Pharmaceutical (Taiwan)
   Key Offering: High‑purity MCC for specialty pharmaceutical applications.
   Wei Ming supplies MCC to Taiwanese and regional manufacturers, focusing on stringent quality and low microbial load.
   Sustainability & Growth Initiatives: Emphasis on green chemistry and reduced solvent usage.
   • Launch of high‑purity MCC for injectable use (2024)
   • Implementation of ISO 14001 environmental system
   • Partnership with a leading biotech firm for ODTs
9. Anhui Sunhere Pharmaceutical (China)
   Key Offering: Cost‑effective MCC for large‑volume generics.
   Anhui Sunhere serves the Chinese market with reliable MCC grades and efficient logistics.
   Sustainability & Growth Initiatives: Adoption of renewable energy sources and efficient water recycling.
   • Expansion of production capacity in Anhui (2025)
   • Certification of MCC under USP/EP (2026)
   • Collaboration with local universities for R&D in MCC functionality
10. Shandong Guangda (China)
    Key Offering: High‑purity MCC for specialty formulations and nutraceuticals.
    Shandong Guangda focuses on delivering MCC that meets global pharmacopeia standards for sensitive applications.
    Sustainability & Growth Initiatives: Commitment to zero‑waste manufacturing and renewable energy adoption.
    • Launch of specialty MCC grades (2024)
    • Investment in advanced purification technologies
    • Partnership with a leading CMO for ODT development

Download FREE Sample Report: https://www.24chemicalresearch.com/download-sample/283389/global-medical-grade-microcrystalline-cellulose-market

Get Full Report: https://www.24chemicalresearch.com/reports/283389/global-medical-grade-microcrystalline-cellulose-market

Outlook

Global demand for medical grade MCC is set to rise steadily as pharmaceutical companies continue to expand generic drug production and invest in advanced dosage forms such as orally disintegrating tablets (ODTs) and controlled‑release systems. The market is expected to maintain a CAGR of around 7% through 2034, driven by regulatory tightening, increasing chronic disease prevalence, and a shift toward high‑purity excipients for biologics.

Future Trends

• Co‑processing of MCC with silicates or gums to create multifunctional excipients.
• Growth of biologics and ODTs driving demand for high‑purity, low‑microbial MCC.
• Expansion into emerging economies in Asia‑Pacific and Latin America to capture cost‑competitive market share.
• Adoption of renewable energy and circular economy practices across MCC manufacturing.
• Integration of digital supply‑chain tools to enhance traceability and quality assurance.